XPRIZE
31.5.2019 21:28:12 CEST | Business Wire | Press release
Today, XPRIZE , the global leader in designing and operating incentive competitions to solve humanity’s grand challenges, has announced winners in the $7M Shell Ocean Discovery XPRIZE , a global competition to advance ocean technologies for rapid, unmanned and high-resolution ocean exploration and discovery.
The results were revealed at an awards ceremony hosted at the world-renowned Oceanographic Museum of Monaco, part of the Oceanographic Institute, Prince Albert I of Monaco Foundation. The grand prize winner, receiving a total of $4M, was GEBCO-NF Alumni , an international team based in the United States, while KUROSHIO , from Japan, claimed $1M as the runner-up:
- GEBCO-NF (International) – Led by Rochelle Wigley, Ph.D. and Yulia Zarayskaya, Ph.D., the 14-nation team integrated existing technologies and ocean-mapping experience with a robust and low-cost unmanned surface vessel, the SeaKIT, along with a novel cloud-based data processing system that allows for rapid seabed visualization, to contribute towards comprehensive mapping of the ocean floor by 2030.
- KUROSHIO (Yokosuka, Japan) – Led by Takeshi Nakatani, Ph.D., the team integrated technologies from their partners to create a surface vessel and software platform that can operate with different autonomous underwater vessels, which increases the versatility of their technology.
The $1M National Oceanic and Atmospheric Administration (NOAA) Bonus Prize for teams to develop technology that could detect a chemical or biological signal underwater and autonomously track it to its source was split between junior high school team Ocean Quest from San Jose, California, claiming $800K as the winner, and Tampa Deep Sea Xplorers , from Florida, taking $200K as runner-up.
“Currently, more than 80 percent of the world’s ocean is unmapped, and I'm proud to have worked alongside the people who will change this as a part of this XPRIZE,” said Executive Director of the Ocean Discovery XPRIZE, Jyotika Virmani, Ph.D. “Our vision is that these new technologies will enable the discovery of new ocean species, underwater resources, geological features, and safer methods of exploring the deep sea, while illuminating the mysteries of the deep and discovering what has remained unknown since the dawn of time.”
Additionally, the judges unanimously recommended a $200K “Moonshot Award” for Team Tao from the United Kingdom for its unique approach to seafloor mapping, even though they did not meet the criteria of the competition.
“The Ocean Discovery XPRIZE teams' accomplishments are a true reflection of XPRIZE’s core belief that incentivizing the crowd will drive innovation and investment, leading to a massive shift in the state of the market,” said Anousheh Ansari, CEO of XPRIZE. “It is an honor to celebrate the winning teams GEBCO-NF Alumni, KUROSHIO, Ocean Quest, Tampa Deep Sea Xplorers, as well as Team Tao for their unprecedented, radical approach. We look forward to watching these pioneers shape the future of ocean exploration and discovery.”
To determine winners, the panel of independent judges reviewed data from field testing conducted in Kalamata, Greece and Ponce, Puerto Rico. In Kalamata, teams had up to 24 hours to map at least 250 km2 of the ocean seafloor at 5m horizontal resolution or higher. The gold-standard high-resolution baseline maps, against which the team maps were judged, were provided by Ocean Infinity and Fugro, while Esri, the global leader in geographic information system (GIS) software and geodatabase management, donated its award-winning ArcGIS Online platform for the teams and judges to use.
“At Shell, we are firm believers in the power of ideas and the value of collaboration to solve big problems,” said Martin Stauble, Shell’s Vice President Exploration North America and Brazil. “We are proud to be part of the Shell Ocean Discovery XPRIZE. This prize energized teams from across the globe and stimulated innovation, technology and learning, all in support of providing data for a better understanding of our oceans. We hope that the XPRIZE results will be a catalyst to create a step-change in the speed and quality of data that companies, research institutes and society can use.”
As part of the total $7M prize purse, four teams opted to compete for the $1M NOAA Bonus Prize. In a field test in Ponce, Puerto Rico, teams needed to demonstrate that their technology can “sniff out” a specified object in the ocean by first detecting and then tracing a biological or chemical signal to its source. The judges determined that no single team was able to trace the signal to its source in the timeframe allowed, so the prize was divided among the two teams that came the closest.
Last year, nine finalist teams were awarded an equal share of the first $1M of the $7M prize purse, in recognition of their progress-to-date and to support the teams’ continued technological development.
“NOAA is proud to support this important competition that is accelerating the development of new unmanned tools capable of tracking chemical and biological signals in our ocean,” said Neil Jacobs, Ph.D., acting NOAA administrator. “The cutting-edge technologies that have emerged as a result of the NOAA Bonus Prize will help fuel a growing Blue Economy and inspire future innovation.”
As part of its post-prize impact work, XPRIZE announced a partnership with Seabed 2030, a collaborative project between The Nippon Foundation and The General Bathymetric Chart of the Oceans (GEBCO) to inspire the complete mapping of the world’s ocean by 2030 and to compile all bathymetric data into the freely-available GEBCO Ocean Map.
Additionally, and in anticipation of World Oceans Day on June 8th, XPRIZE will launch a science fiction ocean anthology featuring 19 original short stories and artwork set in a future when technology has helped unlock the secrets of the world’s oceans.
For more information, visit oceandiscovery.xprize.org .
About XPRIZE
XPRIZE designs and operates multi-million-dollar, global competitions to incentivize the development of technological breakthroughs that accelerate humanity toward a better future. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, the $10 Million ANA Avatar XPRIZE and the $5 Million IBM Watson AI XPRIZE. For more information, visit xprize.org .
About Royal Dutch Shell
Shell has been a technology pioneer for more than 100 years, and has come up with many industry-transforming “firsts” to deliver energy its customers and partners need. Since 2007, Shell has spent more than $1 billion annually on research and development. In 2014, our research and development expenditures were $1.2 billion. Shell’s technical and engineering staff amount to more than 43,000.
Shell companies have operations in more than 70 countries and territories with businesses including oil and gas exploration and production; production and marketing of liquefied natural gas and gas to liquids; manufacturing, marketing and shipping of oil products and chemicals and renewable energy projects. Royal Dutch Shell plc is incorporated in England and Wales, has its headquarters in The Hague and is listed on the London, Amsterdam, and New York stock exchanges. For further information, visit www.shell.com .
About National Oceanic and Atmospheric Administration (NOAA)
The National Oceanic and Atmospheric Administration (NOAA) is a science-based federal agency within the Department of Commerce with regulatory, operational and information service responsibilities with a presence in every state and U.S. territories. NOAA's mission is to understand and predict changes in the Earth's environment, from the depths of the ocean to the surface of the sun, and to conserve and manage coastal and marine resources. For more information, visit www.noaa.gov .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190531005539/en/
Contact:
Eric Desatnik & Katherine Schelbert 310.741.4880 / eric@xprize.org katherine.schelbert@xprize.org
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
